These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33008494)

  • 1. Harnessing Natural Killer Cell Function for Genitourinary Cancers.
    Bhardwaj N; Farkas AM; Gul Z; Sfakianos JP
    Urol Clin North Am; 2020 Nov; 47(4):433-442. PubMed ID: 33008494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel immunotherapies in GU malignancies.
    Drakaki A; McDermott DF
    Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Overview of Emerging Immunotargets of Genitourinary Tumors.
    Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M
    Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy in uropathology].
    Verkarre V; Roussel H; Granier C; Tartour E; Allory Y
    Ann Pathol; 2017 Feb; 37(1):90-100. PubMed ID: 28111042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoembryonic antigen in patients with urologic cancers.
    Guinan P; Ablin RJ; Barakat H; John T; Sadoughi N; Bush IM
    Urol Res; 1973 Oct; 1(3):101-5. PubMed ID: 4804082
    [No Abstract]   [Full Text] [Related]  

  • 6. [The studies of natural killer cell activity in uro-genital cancer patients--investigation of natural killer cell activity from the standpoint of stage and antitumor therapy of genito-urinary tract carcinomas].
    Fukasawa K
    Nihon Hinyokika Gakkai Zasshi; 1988 Feb; 79(2):239-45. PubMed ID: 3226000
    [No Abstract]   [Full Text] [Related]  

  • 7. [Studies on human natural killer (NK) cell activity against cell lines derived from malignant urinary tract tumors. Part 3: Effects of OK432 on human NK cell activity and proliferation of tumor cells].
    Hayakawa M; Marumo K; Nagakura K; Hata M; Fujioka T; Nakamura H; Murai M
    Nihon Hinyokika Gakkai Zasshi; 1984 Jul; 75(7):1124-33. PubMed ID: 6542157
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination immunotherapy in genitourinary malignancies.
    Hoffman-Censits J; Wilde L
    Curr Opin Urol; 2016 Nov; 26(6):523-8. PubMed ID: 27517637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
    Bigot F; Bonnet C; Massard C
    Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination radiotherapy-immunotherapy in genitourinary cancer].
    Ollivier L; Guimas V; Rio E; Vaugier L; Masson I; Libois V; Labbé M; Fradin D; Potiron V; Supiot S
    Cancer Radiother; 2021 Oct; 25(6-7):565-569. PubMed ID: 34391648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latest progress in molecular biology and treatment in genitourinary tumours.
    González-Del-Alba A; Arranz JÁ; Bellmunt J; Maroto JP; Fernández-Calvo O; Valderrama BP; González-Billalabeitia E; Méndez-Vidal MJ; Cassinello J; Romero-Laorden N; Climent MÁ; Puente J; Peláez I; Lázaro-Quintela M; Gallardo E; Suárez C
    Clin Transl Oncol; 2020 Dec; 22(12):2175-2195. PubMed ID: 32440915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunology of genitourinary tumors.
    Guinan P; Sadoughi N; Bush IM; John T; Eghrari F; Ablin RJ
    Urology; 1973 Nov; 2(5):493-9. PubMed ID: 4131868
    [No Abstract]   [Full Text] [Related]  

  • 13. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in genitourinary neoplasia.
    Droller MJ
    J Urol; 1985 Jan; 133(1):1-5. PubMed ID: 2578065
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy in genitourinary malignancies.
    Wattenberg MM; Fong L; Madan RA; Gulley JL
    Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
    Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
    Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [DGFIT: Immune and targeted therapy in urologic oncology – what can be expected?].
    Hegele A; Heinzer H; Rüttinger D; Siebels M
    Aktuelle Urol; 2012 Jul; 43(4):219-26. PubMed ID: 23035262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of treatment on delayed cutaneous hypersensitivity responses (DNCB, croton oil, and recall antigen) in patients with genitourinary cancer.
    Elhilali MM; Brosman SA; Vescera C; Paul JG; Fahey JL
    Cancer; 1978 May; 41(5):1765-70. PubMed ID: 647626
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing NK Cells for Cancer Treatment.
    Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
    Front Immunol; 2019; 10():2836. PubMed ID: 31867006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.